Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study (Q26772965)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Ping-Tao Tseng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

Yen-Wen Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

Weilun Chung

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

Kun-Yu Tu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

Ching-Kuan Wu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

Pao-Yen Lin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

January 2016

0 references

1 January 2016

4 references

7 November 2019

19 November 2019

24 January 2021

25 January 2021

5 references

7 November 2019

19 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

24 January 2021

25 January 2021

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

e2475

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 4.0 International

11 June 2020

copyright license

4 references

7 November 2019

19 November 2019

24 January 2021

Off-label use of sodium valproate for schizophrenia

25 January 2021

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

The neurobiology of antiepileptic drugs

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Bias in meta-analysis detected by a simple, graphical test

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

The positive and negative syndrome scale (PANSS) for schizophrenia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Single-dose intravenous administration of antiepileptic drugs induces rapid and reversible remodeling in the brain: Evidence from a voxel-based morphometry evaluation of valproate and levetiracetam in rhesus monkeys

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

DNA methylation and demethylation as targets for antipsychotic therapy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Prescription patterns of psychotropic medications for the treatment of psychotic disorders in the largest mental health institutions of Uganda

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Management of treatment resistance in schizophrenia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Antiepileptic drug mechanisms of action

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Functional hallucinations in schizophrenia responding to adjunctive sodium valproate.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Adjunct extended-release valproate semisodium in late life schizophrenia

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Combined treatment of schizophrenic psychoses with haloperidol and valproate

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Effective Treatment With Clozapine and Valproate for Refractory Schizophrenia-Like Psychosis After Cerebellar Hemorrhage

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Valproate induces DNA demethylation in nuclear extracts from adult mouse brain

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

A review of valproate in psychiatric practice

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Clinical implications of Brief Psychiatric Rating Scale scores

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

What does the PANSS mean?

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Valproate for hostility in schizophrenia patients.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Divalproex as a calmative adjunct for aggressive schizophrenic patients

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Valproic acid and risperidone

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5291556

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

28 November 2018

1 reference

12 December 2020

Augmentation of risperidone with valproic acid

1 reference

12 December 2020

Treatment of resistant schizophrenia with valproate and neuroleptic drugs

1 reference

12 December 2020

Valproic acid augmentation in clozapine-associated hand-washing compulsion

1 reference

12 December 2020

Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients

1 reference

12 December 2020

Valproic acid and risperidone

1 reference

12 December 2020

Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders

1 reference

12 December 2020

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

1 reference

12 December 2020

Efficacy of Topiramate, Valproate, and Their Combination on Aggression/Agitation Behavior in Patients With Psychosis

1 reference

12 December 2020

Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients

1 reference

12 December 2020

Edema associated with addition of risperidone to valproate treatment

1 reference

12 December 2020

10.1097/MD.0000000000002475

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

release_fdwra6u4ubcfjikr6gbi2ia3be

11 June 2020

Fatcat ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26825886 AND SRC:MED&resulttype=core&format=json

11 June 2020

PubMed publication ID

26825886

1 reference